# Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

> **NCT07084610** · PHASE2 · RECRUITING · sponsor: **Hospital das Clínicas de Ribeirão Preto** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)

## Key facts

- **NCT ID:** NCT07084610
- **Lead sponsor:** Hospital das Clínicas de Ribeirão Preto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-07
- **Final completion:** 2029-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07084610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07084610, "Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07084610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*